2023-504746-54-00RecruitingPhase 1
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Tranquis Therapeutics Inc.1 site in 1 country16 target enrollmentStarted: October 11, 2023Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 16
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Rauno Oja
Scientific
Tranquis Therapeutics Inc.
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 3
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss.Androgenetic Alopecia2023-504421-39-00Cassiopea S.p.A.629
Recruiting
Phase 2
Topical Ketotifen 0.25% for Secondary VestibulodyniaNCT07257029Center for Vulvovaginal Disorders54
Recruiting
Phase 2
Phase II/III clinical study to assess the immunogenicity and safety of Tetanus Vaccine (adsorbed)CTRI/2018/07/014919Seasons Biologicals Pvt Ltd
Recruiting
Not Applicable
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants with Amyotrophic Lateral SclerosisNL-OMON56265Denali Therapeutics Inc15
Not yet recruiting
Phase 1
A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar.SchistosomiasisPACTR202307901658960International Vaccine Institute120